Uromodulin in Rheumatoid Arthritis
Клучни зборови
Апстракт
Опис
Uromodulin, also known as Tamm-Horsfall protein, is a protein abundantly excreted in the urine in healthy individuals. It is synthesized in the thick ascending limb of Henle (TALH) and the early distal convoluted tubule. Its biologic function is still obscure; however, some experimental studies indicated that it might serve as an important urinary defense factor against bacterial colonization and stone formation.
There are controversial publications on the frequencies of urinary tract infections and nephrolithiasis in patients with mutations of uromodulin gene. Deposition of mutated uromodulin in the urinary system may lead to tubular cell dysfunction and apoptosis. These alterations may subsequently cause tubular atrophy and interstitial fibrosis . Moreover, the release of abnormal uromodulin after apoptosis through basolateral secretion may elicit an immune response which may give rise to an immune-mediated tubulointerstitial nephritis .
Uromodulin can activate the other components of the immune system and may modulate the inflammatory and immune responses through different mechanisms .
Experimental studies yielded that uromodulin negative mice displayed splenomegaly with infiltration of white pulp by macrophages and increased levels of TNF-α and interleukin-1 . Rheumatoid arthritis is a systemic autoimmune condition that may eventually result in the joint damage, disability and premature mortality.
Датуми
| Последен пат проверено: | 04/30/2019 |
| Прво доставено: | 05/03/2019 |
| Поднесено е проценето запишување: | 05/30/2019 |
| Прво објавено: | 06/02/2019 |
| Последното ажурирање е доставено: | 05/30/2019 |
| Последно ажурирање објавено: | 06/02/2019 |
| Крај на датумот на започнување на студијата: | 04/30/2017 |
| Проценет датум на примарно завршување: | 04/30/2018 |
| Проценет датум на завршување на студијата: | 05/31/2018 |
Состојба или болест
Фаза
Групи за раце
| Рака | Интервенција / третман |
|---|---|
| ra patients The diagnosis of RA was based on the criteria developed by the American College of Rheumatology and European League Against Rheumatism (ACR/EULAR) in 2010 [8]. A drug history was obtained from every patient. All non-steroidal anti-inflammatory medications and disease-modifying antirheumatic drugs prescribed during the year before enrollment in the study were recorded. criteria included systemic diseases (renal failure, hepatic insufficiency, diabetes mellitus, other collagen vascular diseases, history of smoking and consumption of alcohol.In order to eliminate the possibility of any systemic disease therefore we choose that our control group as young. | |
| healthy control healthy person, similar population |
Критериуми за подобност
| Возраст подобни за студии | 18 Years До 18 Years |
| Полови квалификувани за студии | All |
| Метод на земање примероци | Probability Sample |
| Прифаќа здрави волонтери | Да |
| Критериуми | Inclusion Criteria: - Patients who diagnosed of rheumatoid arthritis as criteria of ACR/EULAR 2010. - All patients age range is 18-80 years. Exclusion Criteria : - Renal failure - Hepatic insufficiency - Diabetes mellitus - Other collagen vascular diseases, - History of smoking and consumption of alcohol |
Исход
Мерки на примарниот исход
1. Patients with rheumatoid arthritis [1 day]
2. A.joint involvement [1 day]
3. B.Serology (at least 1 test result is needed for classification) [1 day]
4. C.Acute-phase reactants (at least 1 test result is needed for classification) [1 day]
5. D.Duration of symptoms [1 day]
6. Uromodulin measure [1 day]
Секундарни мерки на исходот
1. CKD-EPI (Chronic Kidney Disease Epidemiology Colloboration) [1 day]
2. MDRD (Modification of Diet in Renal Disease) [1 day]
3. Urea measure [1 day]
4. Creatinine measure [1 day]
5. Sedimantation measure [1 day]
6. pH measure [1 day]
7. Microalbuminuria measure [1 day]
